Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response.
immunohistochemistry
immunotherapy
malignant melanoma
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
08
04
2019
accepted:
12
07
2019
entrez:
10
12
2019
pubmed:
10
12
2019
medline:
10
12
2019
Statut:
ppublish
Résumé
In difference to other solid malignancies, the identification of biomarkers for the prediction of malignant melanoma (MM) response to immunotherapy is limited. The aim of the current study was to evaluate the immunohistochemical (IHC) expression of MMR proteins in a cohort of MM metastatic patients receiving anti PD-1 treatments. The therapeutic response of patients was also retrospectively assessed. The cohort of the current study included 14 patients with advanced MM that had received anti PD-1 from January 2014 to December 2016 (12 males, 2 females; average age, 71 years; age range, 47-88 years). IHC analysis of MLH1, PMS2, MSH2 and MSH6 proteins was performed on paraffin-embedded primary tumor samples from each patient and on the 23 available metastasis specimens obtained from the Division of Pathology (University of Modena and Reggio Emilia). The results revealed that 7% of the primary melanoma tissue obtained from the patient cohort exhibited the loss of expression of at least one MMR protein. Three samples from one patient, including one primary melanoma and two metastases, exhibited no MSH6 expression and had the most successful response to anti PD-1 treatment, with a progression-free survival and overall survival of 956 and 2,546 days, respectively. In conclusion, the assessment of MMR protein expression represents a potential predictive marker that may have critical importance for patients with primary and metastatic MM, primarily as criterion for the adoption of immunotherapy treatments.
Identifiants
pubmed: 31814971
doi: 10.3892/mco.2019.1946
pii: MCO-0-0-1946
pmc: PMC6888216
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3-8Informations de copyright
Copyright: © Ponti et al.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Exp Dermatol. 2019 Jul;28(7):829-835
pubmed: 31034104
Clin Cancer Res. 2005 Dec 1;11(23):8332-40
pubmed: 16322293
Am J Surg Pathol. 2004 Dec;28(12):1553-9
pubmed: 15577673
J Invest Dermatol. 2002 Jan;118(1):79-86
pubmed: 11851879
Cancer Treat Rev. 2016 Jul;48:61-8
pubmed: 27362548
Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5):null
pubmed: 28619747
Br J Dermatol. 2008 Jul;159(1):162-8
pubmed: 18460031
Int J Cancer. 1999 Mar 1;80(5):744-50
pubmed: 10048977
Hematology. 2018 Mar;23(2):77-82
pubmed: 28728506
J Invest Dermatol. 2006 Oct;126(10):2302-7
pubmed: 16826164
Anticancer Res. 2017 Dec;37(12):7043-7048
pubmed: 29187493
Bull Cancer. 2019 Feb;106(2):105-113
pubmed: 30342749
J Gastrointest Oncol. 2016 Oct;7(5):713-720
pubmed: 27747085
J Am Acad Dermatol. 2013 Mar;68(3):509-10
pubmed: 23394915
Oncotarget. 2017 Aug 24;8(44):77415-77423
pubmed: 29100397
Cell Physiol Biochem. 2017;42(6):2267-2280
pubmed: 28848143
Mod Pathol. 2006 Jul;19(7):950-7
pubmed: 16619000
Int J Oncol. 2015 Oct;47(4):1189-202
pubmed: 26315971
Cancer. 2005 Mar 1;103(5):1018-25
pubmed: 15662714
Oncoimmunology. 2017 Jan 6;6(2):e1277308
pubmed: 28344892